# Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine

> **NCT02505477** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 51 (actual)

## Conditions studied

- Schizophrenia
- Cognitive Deficits
- Schizophrenia; Negative Type

## Interventions

- **DRUG:** N-acetylcysteine
- **OTHER:** Treatment as Usual

## Key facts

- **NCT ID:** NCT02505477
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-06
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02505477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02505477, "Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02505477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*